Prostate Cell News Volume 9.01 | Jan 12 2018

TOP STORY

Androgen Receptor Splice Variants Bind to Constitutively Open Chromatin and Promote Abiraterone-Resistant Growth of Prostate Cancer

Through integrated chromatin immunoprecipitation coupled sequencing and RNA sequencing analysis, the authors identified androgen receptor splice variant (ARV)-preferential-binding sites and a set of genes preferentially transactivated by ARVs in castration-resistant prostate cancer cells. [Nucleic Acids Res] Full Article

(Ranked by impact factor of the journal)

A Small Molecule Pin1 Inhibitor Blocks NF-κB Signaling in Prostate Cancer Cells

Scientists utilized molecular docking technique to identify prolyl-isomerase 1 (Pin1) inhibitors from a database of natural product and natural product-like compounds. The action of the hit compounds against Pin1 activity was studied using multiple methods, including a fluorimetric enzymatic assay, co-immunoprecipitation, western blotting, cell thermal shift and other techniques. [Chem Asian J] Abstract

Model-Driven Discovery of Long-Chain Fatty Acid Metabolic Reprogramming in Heterogeneous Prostate Cancer Cells

Researchers integrated transcriptomic data for two clonal subpopulations from a prostate cancer cell line into a genome-scale metabolic network model to explore their metabolic differences and potential vulnerabilities. [PLoS Comput Biol] Full Article

The Microwell-Mesh: A High-Throughput 3D Prostate Cancer Spheroid and Drug-Testing Platform

The authors describe the use of a microwell platform that utilizes a nylon mesh to retain 3D micro-tumors in discrete microwells, termed the Microwell-mesh. [Sci Rep] Full Article

Determining Direct Binders of the Androgen Receptor Using a High-Throughput Cellular Thermal Shift Assay

Scientists report the development of the first high-throughput The Cellular Thermal Shift Assay to identify direct androgen receptor (AR) binders in a prostate cancer cell line endogenously expressing AR. [Sci Rep] Full Article

Effect of FAK Inhibitor Vs-6063 (Defactinib) on Docetaxel Efficacy in Prostate Cancer

Docetaxel and VS-6063 co-treatment caused a greater decrease in the viability of docetaxel-resistant castration-sensitive prostate cancer cells, and a greater inhibition in PC3 xenograft growth compared to either monotherapy. [Prostate] Abstract

DLX1, a Binding Protein of Beta-Catenin, Promoted the Growth and Migration of Prostate Cancer Cells

DLX1 promoted the growth, migration and colony formation of prostate cancer cells by activating beta-catenin/TCF signaling. [Exp Cell Res] Abstract

MicroRNA 200c-3p Regulates Autophagy via Upregulation of Endoplasmic Reticulum Stress in PC-3 Cells

Researchers investigated the role of ectopic expression of miRNA 200c-3p in autophagy. Western blotting and RT-qPCR analysis revealed that ectopic expression of miR-200c-3p increased the expression of inositol requiring protein-1, activating transcription factor-6, and C/EBP homologous protein in PC-3 prostate cancer cells. [Cancer Cell Int] Full Article

Downregulated Expression of Hepatoma-Derived Growth Factor Inhibits Migration and Invasion of Prostate Cancer Cells by Suppressing Epithelial-Mesenchymal Transition and MMP2, MMP9

Hepatoma-derived growth factor knockdown reduced prostate cancer cellular migration and invasion in both androgen-sensitive LNCaP cells and androgen-insensitive DU145 and PC3 cells. [PLoS One] Full Article

Long Interspersed Nuclear Element-1 Expression and Retrotransposition in Prostate Cancer Cells

Investigators examined endogenous long interspersed nuclear element-1 (LINE-1) protein expression and localization in a panel of prostate cancer cells and observed a diverse range of LINE-1 expression patterns between cell lines. [Mob DNA] Abstract

Preclinical Models of Prostate Cancer: Patient-Derived Xenografts, Organoids, and Other Explant Models

Research in the prostate cancer field is hampered by the limited number of human cell lines and xenograft models, most of which do not recapitulate the human disease seen in the clinic today. The authors review recent advances in human patient-derived xenograft, organoid, and other explant models to address this need. [Cold Spring Harb Perspect Med] Abstract

Visit our reviews page to see a complete list of reviews in the prostate cell research field.

Immunomedics Announces Agreement with University of Wisconsin Carbone Cancer Center to Expand Sacituzumab Govitecan (IMMU-132) into Prostate Cancer

Immunomedics, Inc. announced a collaboration with the Carbone Cancer Center at the University of Wisconsin, through Immunomedics entering an agreement with The Prostate Cancer Clinical Trials Consortium, to investigate Immunomedics’ lead antibody-drug conjugate product candidate, sacituzumab govitecan, in an investigator-sponsored Phase II trial in patients with advanced castration-resistant prostate cancer. [Immunomedics, Inc. (GlobeNewswire, Inc.)] Press Release

Progenics Pharmaceuticals Completes Enrollment in Phase III Study of PSMA-Targeted Imaging Agent 1404

Progenics Pharmaceuticals, Inc. announced that it has completed enrollment in its Phase III study of 1404, a prostate specific membrane antigen (PSMA)-targeted small molecule SPECT/CT imaging agent that is designed to visualize prostate cancer. [Progenics Pharmaceuticals, Inc.] Press Release

70% of Advanced Prostate Cancer Patients Treated with ProscaVax Demonstrate Improvement in PSA Doubling Time

OncBioMune Pharmaceuticals, Inc. announced the latest follow-up data from the company’s Phase Ia trial of ProscaVax for prostate cancer. ProscaVax is OncBioMune’s novel immunotherapeutic cancer vaccine consisting of a combination of prostate cancer associated prostate specific antigen (PSA) with the biological adjuvants interleukin-2 and granulocyte-macrophage colony-stimulating factor. [OncBioMune Pharmaceuticals, Inc.] Press Release

Rising Star Appointed UK Science Minister

The United Kingdom has gained a new science minister as part of a broader reshuffle of government posts. Sam Gyimah, who moves from the Ministry of Justice, was appointed minister for universities and science, replacing Jo Johnson. [Nature News] Editorial

Faced with Public Pressure, Research Institutions Step Up Reporting of Clinical Trial Results

The reporting of clinical trial results to a public database — mandated by a ten-year-old federal law — has improved sharply in the last two years, with universities and other nonprofit research centers leading the way. [STAT News] Editorial

NEW American Urological Association (AUA) Annual Meeting 2018
May 18-21, 2018
San Francisco, California, United States

Visit our events page to see a complete list of events in the community.

NEW Postdoctoral Position – Molecular Imaging and Radionuclide Therapy in Prostate Cancer (Klinikum rechts der Isar)

NEW Professor, Tenure Canada Excellence Research Chair – Precision Cancer Drug Design (University of British Columbia)

Assistant Professor, Associate Professor & Professor – Cell & Molecular Biology (University of Mississippi)

Postdoctoral Positions – Gene Regulation and/or Cancer Biology (University of North Carolina)

Postdoctoral Scientist – Prostate Oncobiology (CRUK Manchester Institute)

Assistant/Associate Professor – Prostate Cancer (Northwestern University)

Postdoctoral Fellowship – Prostate Cancer (Duke University Medical Center)

PhD Studentship – Prostate Cancer (CRUK Manchester Institute)

Postdoctoral Position – Prostate Cancer (Baylor College of Medicine)

Postdoctoral Position – Prostate Related Diseases (Baylor College of Medicine)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here.